anagrelide


Also found in: Wikipedia.

anagrelide

 [an-ag´rĕ-līd]
an agent used in the form of the hydrochloride salt to reduce elevated platelet counts and the risk of thrombosis in treatment of hemorrhagic thrombocythemia; administered orally.

anagrelide

/an·ag·re·lide/ (an-ag´rĕ-līd) an agent used to reduce elevated platelet counts and the risk of thrombosis in the treatment of hemorrhagic thrombocythemia; used as the hydrochloride salt.

anagrelide

an antiplatelet agent.
indication This drug is prescribed for essential thrombocythemia.
contraindications Known hypersensitivity and hypotension prohibit its use.
adverse effects Life-threatening effects include congestive heart failure, myocardial infarction, myocardiopathy, cardiomegaly, complete heart block, atrial fibrillation, anemia, thrombocytopenia, ecchymosis, and lymphadenoma. Other serious effects include tachycardia, palpitations, arrhythmia, and seizures. Common side effects include orthostatic hypotension and rash.

anagrelide

A cytoreductive agent used to manage essential thrombocythaemia and thrombocythaemia due to myeloproliferative disorders (e.g., CML, polycythemia vera) to reduce platelets, risk of thrombosis and other symptoms. It is generally regarded as a second-line therapy compared to hydroxyurea.

Anagrelide

An orphan drug that is approved for treating PV patients on an investigational basis. Anagrelide works by controlling the level of platelets in the blood.
Mentioned in: Polycythemia Vera
References in periodicals archive ?
NASDAQ: INCY) has treated the first patient in the RESET pivotal trial evaluating ruxolitinib (Jakafi) compared to anagrelide for the treatment of patients with essential thrombocythemia (ET) who are resistant to or intolerant of hydroxyurea (HU), the company said.
La PV y TE se manejan con aspirina, flebotomias, uso selectivo de hidroxicarbamida-hydrea, interferon alfa (IFNa) o anagrelide (5).
This planned Phase 3 clinical trial will enroll patients with essential thrombocythemia who have either failed or are intolerant to hydroxyurea, and will compare GALE-401 to the best available therapy (BAT) that will include a sizable subpopulation of patients treated with anagrelide immediate release, added the company.
SOME DRUGS THAT CAN CAUSE OR EXACERBATE HEART FAILURE Condition Drugs Arrhythmia dronedarone, flecainide, disopyramide, sotalol Cancer anthracydines and many other agents Depression citalopram, lithium Diabetes thiazolidinediones, dipeptidyl peptidase-4 inhibitors Fungal infections amphotericin B Hypertension doxazosin, diltiazem, verapamil, moxonidine Malaria chloroquine, hydroxychloroquine Migraines ergotamine, methysergide Pain prescription and nonprescription NSAIDs Parkinson's pergolide, pramipexole, bromocriptine Platelet disorders anagrelide, cilostazol Pulmonary disease bosentan, epoprostenol, albuterol Rheumatologic TNF-a inhibitors diseases
Progression of bone marrow fibrosis in patients with essential thrombocythemia and polycythemia vera during anagrelide treatment.
d, Anagrelide (5) 1mg bid, Alpha Interferon (6) 3 million daily are best options to reduce the platelet counts in E.
The acquired business holds the worldwide rights to GALE-401 (Anagrelide CR), a patented, controlled release formulation of anagrelide.
Long-term use of anagrelide in young patients with essential thrombocythemia.
Treatment is focused on lowering RBC mass to prevent hyperviscosity either by simple method of therapeutic phlebotomy and/or by administration of myelosuppressive agents such as hydroxyurea or anagrelide.
For pediatric use, anagrelide or hydroxyurea is recommended.
Following an initial medical treatment with nitrates, beta-blockers, angiotensin converting enzyme inhibitors, aspirin, statins, sedatives and continuing anti-platelet therapy with Anagrelide (Thromboreductin[TM]--AOP Orphan Pharmaceuticals, Austria) a coronary angiogram was performed, revealing an irregular 90% stenotic lesion of the proximal left anterior descending (LAD) and first diagonal coronary arteries.